Law360, New York (May 21, 2015, 12:12 PM EDT) -- In an April 22, 2015, letter to the New York State Department of Health, the Federal Trade Commission cautioned that part of the state's Medicaid reform program may generate anti-competitive behavior. The FTC's concern stems from the state's Certificate of Public Advantage ("COPA") regulations,[1] which offer federal antitrust immunity for certain collaborations among providers participating in the Delivery System Reform Incentive Payments ("DSRIP") program. Specifically, the FTC expressed its "strong concern" that COPAs immunize collaborative activities that otherwise may be impermissible under federal antitrust laws, and may "lead to increased health care costs and decreased access to health care services for New York consumers."...